

QIAGEN NV  
Form SD  
May 17, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM SD  
Specialized Disclosure Report

---

Commission File Number 001-38332

---

QIAGEN N.V.  
(Exact name of Registrant as specified in its charter)  
n/a  
(Translation of Registrant's name in English)  
The Netherlands  
(Jurisdiction of incorporation or organization)  
Hulsterweg 82  
5912 PL Venlo  
The Netherlands  
011-31-77-355-6600  
(Address of principal executive offices)

---

Roland Sackers, Tel: 011-31-77-355-6600, Fax: 011-31-77-355-6658  
QIAGEN N.V., Hulsterweg 82, 5912 PL Venlo, The Netherlands  
( Name and telephone number, including area code, of the person to contact in connection with this report.)

---

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:  
☒ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017.

---

## Section 1 - Conflict Minerals Disclosure

### Item 1.01 Conflict Minerals Disclosure and Report

QIAGEN N.V. (the “Company”) has evaluated its product offerings for the calendar year ended December 31, 2017 and determined that certain “conflict minerals” are necessary to the functionality or production of certain instrumentation products it manufactures or contracts to manufacture. After conducting a reasonable country of origin inquiry (“RCOI”) with the suppliers of certain components used in these products, the Company has concluded that its products are “DRC conflict free” as further described below. The determination of the conflict minerals status of its products is also posted on its website: <http://www.qiagen.com/about-us/investors/financial-information/financial-reports/other-reports/> under the heading “Conflict Minerals Disclosure.”

#### Conflict Minerals Disclosure

The Company performed a comprehensive analysis of its automation and instrumentation components and identified all suppliers of the components that may contain “conflict minerals” which are columbite-tantalite, cassiterite, gold, wolframite, and their derivatives, which are limited to tin, tungsten and tantalum. The Company defined the scope of its RCOI to include all 28 of these direct suppliers. The Company began its conflict minerals inquiries of these direct suppliers in the fourth quarter of 2017 and received responses from the direct suppliers which were either provided on company letterhead or on standard conflict minerals reporting templates established by the Electronic Industry Citizenship Coalition (EICC). The Company conducted its RCOI in good faith and believes that its inquiry was reasonably designed to determine whether any of the conflict minerals originated in the Democratic Republic of the Congo or any adjoining country (the “DRC”). In conducting this inquiry, the Company relied on the direct suppliers’ responses about the source of conflict minerals contained in the components supplied to it. These direct suppliers to the Company are similarly reliant upon information provided by their suppliers.

The Company received responses to its request for information from all direct suppliers within the scope of the RCOI. Of these 28 responses, all 28 confirmed that the products they supply to the Company are either DRC conflict free or they are not aware of any non-compliance in their supply base.

Based on the RCOI, the Company has no indication that any conflict minerals used in its products in the calendar year ended December 31, 2017 originated in the DRC. Further, based on the Company’s knowledge to date, it has no reason to believe that the conflict minerals used in its products originated in the DRC. Accordingly, the Company has determined that as of December 31, 2017, its products are DRC conflict free.

#### Item 1.02 Exhibit.

Not applicable.

## Section 2 - Exhibits

### Item 2.01 Exhibits.

None.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

QIAGEN N.V.

BY: /S/ ROLAND SACKERS  
Roland Sackers  
Chief Financial Officer

Date: May 16, 2018